Michael Schmertzler

Michael Schmertzler is Chairman at PTC Therapeutics, Inc. since 2004.
Holds director positions at Dispel LLC, The LOR Foundation, Inc., AgNovos Healthcare LLC, Berryville Holdings LLC since 2014, SHY Therapeutics LLC since 2015, and Phillips Academy Andover since 2021.
Independent Director at Hamilton Lane, Inc. starting 2026.
Formerly Chief Executive Officer & Director at Kolltan Pharmaceuticals, Inc. in 2012.
Served as Director at Cytokinetics, Inc. from 2003 to 2010.
Managing Director at Aries Advisors LLC from 2001 to 2015.
Managing Director at CSFB Private Equity Partners LLC from 1997 to 2001.
Senior Manager-Institutional Private Equity at Credit Suisse First Boston Equity Partners LP from 1986 to 2001.
Principal at Credit Suisse First Boston LLC in 2001.
Held director roles at Coltec Industries, Inc., Idenix Pharmaceuticals LLC, Segway, Inc., Lehman Commercial Paper, Inc., New York Academy of Sciences, Manhattan Theatre Club, Inc., Colt Industries, Inc., National Outdoor Leadership School, Cain Chemical, Inc., Credit Suisse Americas Foundation, and The Addison Gallery of American Art.
Managing Director & Chief Financial Officer at Lehman Brothers, Kuhn, Loeb, Inc. Head-International Sales & Trading at Lehman Brothers, Inc. President at Morgan Stanley Leveraged Capital Fund, Inc. Head-International Investment Banking at Shearson Lehman Brothers, Inc. Education includes an MBA from Harvard Business School and an undergraduate degree from Yale College conferred in 1998.